【24h】

Heat shock proteins in breast cancer progression–A suitable case for treatment?

机译:乳腺癌进展中的热激蛋白是否适合治疗?

获取原文
       

摘要

Heat shock proteins (HSP) and heat shock factor 1 (HSF1), key factors in the heat shock response (HSR) have been implicated in the etiology of breast cancer. At least two members of the HSP family, Hsp27 and Hsp70 undergo significant increases in cellular concentration during the transformation of mammary cells. These changes result in HSP-mediated inhibition of tumour cell inactivation through blockade of the apoptosis and replicative senescence pathways. The increases in HSP thus mediate two of the common hallmarks of cancer and favour cell birth over cell death. In addition, Hsp90 plays a role in facilitating transformation by stabilising the mutated and over-expressed oncoproteins found in breast tumours, and permitting the activation of growth stimulatory and transforming pathways in the absence of growth factors. HSF1 appears to play a similar role as a facilitator of transformation in mammary carcinoma. Induction of some facets of the HSR in breast cancer cells therefore leads to growth stimulation and inhibits cell death. Pharmacological targeting of HSP and HSF1 is therefore indicated and in the case of Hsp90, inhibitory drugs are undergoing clinical trial for treatment of breast carcinoma and other cancers.
机译:热休克蛋白(HSP)和热休克因子1(HSF1)是热休克反应(HSR)的关键因素,已与乳腺癌的病因有关。 HSP家族中的至少两个成员Hsp27和Hsp70在乳腺细胞转化过程中细胞浓度显着增加。这些改变通过阻断细胞凋亡和复制性衰老途径而导致HSP介导的对肿瘤细胞失活的抑制。因此,热休克蛋白的增加介导了癌症的两个共同特征,并倾向于细胞出生而不是细胞死亡。此外,Hsp90通过稳定在乳腺肿瘤中发现的突变和过表达的癌蛋白,并在缺乏生长因子的情况下激活生长刺激和转化途径,在促进转化中发挥作用。 HSF1似乎在乳癌中起转化促进剂的作用类似。因此,在乳腺癌细胞中诱导HSR的某些方面会导致生长刺激并抑制细胞死亡。因此表明了对HSP和HSF1的药理靶向作用,在Hsp90的情况下,抑制性药物正在接受临床试验以治疗乳腺癌和其他癌症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号